Mostrar el registro sencillo del ítem
Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG)
dc.creator | Christodoulou C., Kalogera-Fountzila A., Karavasilis V., Kouvatseas G., Papandreou C.N., Samantas E., Varaki K., Papadopoulos G., Bobos M., Rallis G., Razis E., Goudopoulou A., Kalogeras K.T., Syrigos K.N., Fountzilas G. | en |
dc.date.accessioned | 2023-01-31T07:46:17Z | |
dc.date.available | 2023-01-31T07:46:17Z | |
dc.date.issued | 2017 | |
dc.identifier | 10.1007/s11060-017-2548-z | |
dc.identifier.issn | 0167594X | |
dc.identifier.uri | http://hdl.handle.net/11615/72848 | |
dc.description.abstract | Small molecules, mainly tyrosine kinase inhibitors, are currently used in various malignancies. Lapatinib, a dual inhibitor of EGFR/HER2 tyrosine kinases, has demonstrated effectiveness in brain metastases from HER2-overexpressing breast cancer. It also appears to sensitize EGFR-expressing cell lines to radiation. To evaluate the efficacy of lapatinib in combination with whole brain radiotherapy (WBRT) in patients with brain metastases from non-small cell lung cancer (NSCLC) and breast cancer, as assessed by volumetric analysis by MRI. 81 patients were treated with WBRT (30 Gy in ten fractions) in combination with lapatinib 1250 mg once daily, followed by lapatinib 1500 mg once daily for a total 6 weeks. 21 patients had primary breast cancer and 60 patients NSCLC. Pre- and post-treatment MRI scans in a compact disk for central volumetric assessment were available for 43 patients. 27 patients (62.8%) achieved partial response, 15 patients (34.9%) had stable disease and only one patient (2.3%) had disease progression. Response was not associated to EGFR protein expression. All 81 patients were assessed for safety. The large majority of the adverse events were mild. Eight deaths occurred, four of which were considered related to the study drugs but there were also other contributing factors. Nine cases of serious infections were observed in eight patients, but they were also receiving dexamethasone. Lapatinib in combination with WBRT in patients with brain metastases from breast cancer and NSCLC is a feasible approach that can be further studied in larger clinical trials. © 2017, Springer Science+Business Media, LLC. | en |
dc.language.iso | en | en |
dc.source | Journal of Neuro-Oncology | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85021899205&doi=10.1007%2fs11060-017-2548-z&partnerID=40&md5=af9108eb03106f5b3551f8d6f7ffbf51 | |
dc.subject | dexamethasone | en |
dc.subject | epidermal growth factor receptor | en |
dc.subject | lapatinib | en |
dc.subject | antineoplastic agent | en |
dc.subject | lapatinib | en |
dc.subject | quinazoline derivative | en |
dc.subject | adult | en |
dc.subject | Article | en |
dc.subject | bleeding | en |
dc.subject | blood toxicity | en |
dc.subject | bone marrow disease | en |
dc.subject | brain metastasis | en |
dc.subject | brain radiation | en |
dc.subject | breast cancer | en |
dc.subject | cancer chemotherapy | en |
dc.subject | chemoradiotherapy | en |
dc.subject | clinical effectiveness | en |
dc.subject | controlled study | en |
dc.subject | disease association | en |
dc.subject | drug efficacy | en |
dc.subject | drug fatality | en |
dc.subject | drug safety | en |
dc.subject | drug withdrawal | en |
dc.subject | ear disease | en |
dc.subject | feasibility study | en |
dc.subject | female | en |
dc.subject | gastrointestinal disease | en |
dc.subject | heart disease | en |
dc.subject | human | en |
dc.subject | infection | en |
dc.subject | lymphatic system disease | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | metabolic disorder | en |
dc.subject | multicenter study | en |
dc.subject | non small cell lung cancer | en |
dc.subject | nuclear magnetic resonance imaging | en |
dc.subject | open study | en |
dc.subject | pain | en |
dc.subject | patient safety | en |
dc.subject | phase 2 clinical trial | en |
dc.subject | primary tumor | en |
dc.subject | protein expression | en |
dc.subject | radiation dose fractionation | en |
dc.subject | respiratory tract disease | en |
dc.subject | sexual dysfunction | en |
dc.subject | skin disease | en |
dc.subject | soft tissue disease | en |
dc.subject | treatment duration | en |
dc.subject | vascular disease | en |
dc.subject | visual disorder | en |
dc.subject | volumetry | en |
dc.subject | aged | en |
dc.subject | brain | en |
dc.subject | brain tumor | en |
dc.subject | breast tumor | en |
dc.subject | chemoradiotherapy | en |
dc.subject | clinical trial | en |
dc.subject | diagnostic imaging | en |
dc.subject | disease exacerbation | en |
dc.subject | drug effect | en |
dc.subject | follow up | en |
dc.subject | lung tumor | en |
dc.subject | middle aged | en |
dc.subject | non small cell lung cancer | en |
dc.subject | pathology | en |
dc.subject | radiation response | en |
dc.subject | secondary | en |
dc.subject | treatment outcome | en |
dc.subject | very elderly | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Aged, 80 and over | en |
dc.subject | Antineoplastic Agents | en |
dc.subject | Brain | en |
dc.subject | Brain Neoplasms | en |
dc.subject | Breast Neoplasms | en |
dc.subject | Carcinoma, Non-Small-Cell Lung | en |
dc.subject | Chemoradiotherapy | en |
dc.subject | Disease Progression | en |
dc.subject | Female | en |
dc.subject | Follow-Up Studies | en |
dc.subject | Humans | en |
dc.subject | Lung Neoplasms | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Quinazolines | en |
dc.subject | Treatment Outcome | en |
dc.subject | Springer New York LLC | en |
dc.title | Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG) | en |
dc.type | journalArticle | en |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |